收费全文 | 146042篇 |
免费 | 10613篇 |
国内免费 | 514篇 |
耳鼻咽喉 | 1830篇 |
儿科学 | 3502篇 |
妇产科学 | 3255篇 |
基础医学 | 18884篇 |
口腔科学 | 3052篇 |
临床医学 | 14350篇 |
内科学 | 31513篇 |
皮肤病学 | 2125篇 |
神经病学 | 13092篇 |
特种医学 | 5273篇 |
外国民族医学 | 5篇 |
外科学 | 24626篇 |
综合类 | 1871篇 |
现状与发展 | 1篇 |
一般理论 | 151篇 |
预防医学 | 10503篇 |
眼科学 | 3568篇 |
药学 | 9075篇 |
中国医学 | 213篇 |
肿瘤学 | 10280篇 |
2023年 | 848篇 |
2022年 | 1586篇 |
2021年 | 3318篇 |
2020年 | 1866篇 |
2019年 | 2889篇 |
2018年 | 3388篇 |
2017年 | 2408篇 |
2016年 | 2723篇 |
2015年 | 3188篇 |
2014年 | 4556篇 |
2013年 | 6450篇 |
2012年 | 9635篇 |
2011年 | 9877篇 |
2010年 | 5529篇 |
2009年 | 5036篇 |
2008年 | 8788篇 |
2007年 | 9537篇 |
2006年 | 9026篇 |
2005年 | 8999篇 |
2004年 | 8662篇 |
2003年 | 8086篇 |
2002年 | 7909篇 |
2001年 | 1300篇 |
2000年 | 1049篇 |
1999年 | 1292篇 |
1998年 | 1699篇 |
1997年 | 1465篇 |
1996年 | 1205篇 |
1995年 | 1199篇 |
1994年 | 1048篇 |
1993年 | 950篇 |
1992年 | 927篇 |
1991年 | 845篇 |
1990年 | 749篇 |
1989年 | 727篇 |
1988年 | 689篇 |
1987年 | 691篇 |
1986年 | 676篇 |
1985年 | 757篇 |
1984年 | 918篇 |
1983年 | 955篇 |
1982年 | 1142篇 |
1981年 | 1067篇 |
1980年 | 1025篇 |
1979年 | 625篇 |
1978年 | 679篇 |
1977年 | 714篇 |
1976年 | 622篇 |
1975年 | 538篇 |
1974年 | 478篇 |
Purpose
A hydrogel rectal spacer (HRS) is a medical device that is approved by the U.S. Food and Drug Administration to increase the separation between the prostate and rectum. We conducted a cost-effectiveness analysis of HRS use for reduction in radiation therapy (RT) toxicities in patients with prostate cancer (PC) undergoing external beam RT (EBRT).Methods and Materials
A multistate Markov model was constructed from the U.S. payer perspective to examine the cost-effectiveness of HRS in men with localized PC receiving EBRT (EBRT alone vs EBRT + HRS). The subgroups analyzed included site of HRS placement (hospital outpatient, physician office, ambulatory surgery center) and proportion of patients with good baseline erectile function (EF). Data on EF, gastrointestinal and genitourinary toxicities incidence, and potential risks associated with HRS implantation were obtained from a recently published randomized clinical trial. Health utilities and costs were derived from the literature and the 2018 Physician Fee Schedule and were discounted 3% annually. Quality-adjusted life years (QALYs) and costs were modeled for a 5-year period from receipt of RT. Probabilistic sensitivity analysis and value-based threshold analyses were conducted.Results
The per-patient 5-year incremental cost for spacers administered in a hospital outpatient setting was $3578, and the incremental effectiveness was 0.0371 QALYs. The incremental cost-effectiveness ratio was $96,440/QALY for patients with PC undergoing HRS insertion in a hospital and $39,286/QALY for patients undergoing HRS insertion in an ambulatory facility. For men with good baseline EF, the incremental cost-effectiveness ratio was $35,548/QALY and $9627/QALY in hospital outpatient and ambulatory facility settings, respectively.Conclusions
Based on the current Medicare Physician Fee Schedule, HRS is cost-effective at a willingness to pay threshold of $100,000. These results contain substantial uncertainty, suggesting more evidence is needed to refine future decision-making. 相似文献Introduction
Physician communication impacts patient outcomes. However, communication skills, especially around difficult conversations, remain suboptimal, and there is no clear way to determine the validity of entrustment decisions. The aims of this study were to 1) describe the development of a simulation-based mastery learning (SBML) curriculum for breaking bad news (BBN) conversation skills and 2) set a defensible minimum passing standard (MPS) to ensure uniform skill acquisition among learners.Innovation
An SBML BBN curriculum was developed for fourth-year medical students. An assessment tool was created to evaluate the acquisition of skills involved in a BBN conversation. Pilot testing was completed to confirm improvement in skill acquisition and set the MPS.Outcomes
A BBN assessment tool containing a 15-item checklist and six scaled items was developed. Students' checklist performance improved significantly at post-test compared to baseline (mean 65.33%, SD = 12.09% vs mean 88.67%, SD = 9.45%, P < 0.001). Students were also significantly more likely to have at least a score of 4 (on a five-point scale) for the six scaled questions at post-test. The MPS was set at 80%, requiring a score of 12 items on the checklist and at least 4 of 5 for each scaled item. Using the MPS, 30% of students would require additional training after post-testing.Comments
We developed a SBML curriculum with a comprehensive assessment of BBN skills and a defensible competency standard. Future efforts will expand the mastery model to larger cohorts and assess the impact of rigorous education on patient care outcomes. 相似文献Methods: A retrospective cohort design and data from two US healthcare claims repositories were employed. The study population included patients who had non-metastatic cancer of the breast, colon/rectum, lung or ovaries, or non-Hodgkin’s lymphoma (NHL), and who received myelosuppressive chemotherapy regimens with an intermediate/high risk for FN. For each patient, the first cycle of the first course was characterized in terms of PP-CSF use and FN episodes. Crude incidence proportions for PP-CSF and FN during the first cycle were estimated by calendar quarter (2010–2016); multivariable logistic regression models were used to estimate quarter-specific adjusted mean probabilities of FN by PP-CSF use.
Results: The study population totaled 142,730 patients with breast cancer (61%), colorectal cancer (14%), NHL (11%), ovarian cancer (10%) or lung cancer (5%). PP-CSF use increased from 52% in 1Q2010 to 58% in 4Q2016; pegfilgrastim was the most commonly used agent (>96% across quarters). PP-CSF administration on the same day as chemotherapy ranged from 8 to 11% until 1Q2015, and increased to 64% by 4Q2016. Adjusted incidence proportions for FN in the first chemotherapy cycle ranged from 2.7% (95% CI: 2.3–3.0) to 3.7% (95% CI: 3.1–4.3) among those who did not receive PP-CSF, and was 2.6% (95% CI: 2.5–2.7) across quarters among those who received PP-CSF.
Conclusions: Although the use of PP-CSF is commonplace in current US clinical practice, underutilization in cancer patients receiving chemotherapy regimens with an intermediate/high risk for FN may still be an issue. Use of same-day PP-CSF increased markedly from the end of 2015, although this finding reflects (at least in part) increased uptake of pegfilgrastim delivered via an on-body injector as well as the recent change in clinical practice guidelines. Overall, patients receiving PP-CSF appear to have a lower risk of FN during the first cycle of chemotherapy. 相似文献